Overview

A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
0
Participant gender:
Female
Summary
To provide extended access to Ixabepilone therapy to subjects with metastatic breast cancer who have completed the previous Phase II study (CA163-107)
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bristol-Myers Squibb
R-Pharm
Treatments:
Epothilones
Criteria
Inclusion Criteria:

- Women aged 20 years or older

- Patients with metastatic breast cancer whose primary lesion was definitely diagnosed
to be breast by histological or cellular examination

Exclusion Criteria:

- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of
≥2